Why, for instance, can the substances produce severe reactions, triggering schizophrenia or mania in ... at one point ...

Supporters say psychedelics alleviate treatment-resistant conditions like PTSD and depression. Opponents cite health risks ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

The usual age range of a schizophrenia diagnosis is 16 to 30 years old. It’s important to begin treatment for schizophrenia as soon as possible after someone first experiences psychosis.